Compare GXO Logistics Inc (GXO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Novo Nordisk A/S — how do they compare? GXO Logistics Inc trades at $46.63 (market cap $5.32B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 31.1× GXO Logistics Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Novo Nordisk A/S for 116 Days on average.
| GXO | NVO | |
|---|---|---|
Market Cap | $5.32B | $165.31B |
Volume | 1,255,816 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $65.59 | $63.98 |
52-Week Low | $44.17 | $35.29 |
Typical Hold Time | 28 Days | 116 Days |
Enterprise Value | $10.67B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.47, up 1.04% with neutral technical indicators and strong analyst support. The company shows improving fundamentals with Q2 2026 revenue of $3.4 billion (up 4% YoY) and three consecutive earnings beats. Recent strategic partnerships with Columbia Sportswear and technology investments in labor management systems position GXO for operational efficiency gains. The stock trades at a P/E of 41.03 and P/S of 0.39, reflecting growth expectations amid modest current profitability.
GXO presents a compelling growth story with 88.9% analyst buy ratings and a $66.67 consensus price target (43% upside). However, margin compression remains a concern as new business wins show lower incremental profitability. The company's expansion in aerospace/defense and European logistics markets provides growth catalysts, but investors should monitor execution on the 6% EBIT margin target and supply chain industry headwinds.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
